Radial artery as a conduit for coronary artery bypass grafting:a state-of-the-art primer by Sousa-Uva, Miguel et al.
                          Sousa-Uva, M., Gaudino, M., Schwann, T. A., Ruel, M., Acar, C., Nappi, F.,
... Ruel, M. (2018). Radial artery as a conduit for coronary artery bypass
grafting: a state-of-the-art primer. European Journal of Cardio-Thoracic
Surgery, 971-976. [ezy335]. https://doi.org/10.1093/ejcts/ezy335,
https://doi.org/10.1093/ejcts/ezy456
Peer reviewed version
Link to published version (if available):
10.1093/ejcts/ezy335
10.1093/ejcts/ezy456
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Oxford University Press at https://academic.oup.com/ejcts/article/54/6/971/5146781 . Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Radial Artery as a Conduit for Coronary Artery Bypass Grafting: A State of the 
Art Primer 
 
Sousa-Uva M1,2, Gaudino M3, Schwann T4,5, Acar C6, Benedeto U7, Ruel M8. 
 
1 Department of Cardiac Surgery, Hospital Santa Cruz, Carnaxide, Portugal. 
2 Department of Surgery and Physiology, Cardiovascular Research Centre, Faculty of 
Medicine, Porto University, Porto, Portugal. 
3 Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA. 
4 Department of Cardiothoracic Surgery, University of Toledo, Toledo, OH, USA. 
5 Department of Cardiothoracic Surgery, University of Massachusetts - Baystate, Springfield, 
MA, USA. 
6 Department of Cardiac Surgery, Hôpital La Pitié-Salpétriêre, Paris, France. 
7 Department of Cardiac Surgery, Bristol Heart Institute, University of Bristol, Bristol, UK. 
8 Division of Cardiac Surgery, University of Ottawa Heart Institute, University of Ottawa, 
Ottawa, ON, Canada. 
 
Department of Cardiac Surgery, Hospital Santa Cruz, Carnaxide, Portugal 
Department of Surgery and Physiology, Cardiovascular Research Centre,  
Faculty of Medicine, Porto University, Porto, Portugal 
Corresponding author. Department of Cardiac Surgery,  
Hospital Santa Cruz, Avenida Prof Reynaldo dos Santos, 2790-134 Carnaxide,  
Portugal. Tel: +351-210-433163; fax: +351-21-4241388;  
e-mail: migueluva@gmail.com (M. Sousa-Uva). 
 
  
Use of the radial artery (RA) as a conduit for coronary artery bypass grafting (CABG) was 
initially proposed by Carpentier’s group, and has subsequently been the subject of 
numerous observational studies and of several randomized controlled trials (1-6). The RA is 
relatively easy to harvest, can reach all coronary territories without significant size 
mismatch with the coronary vessel, and leads to few if any site-related complications. 
However, the RA’s medial layer is largely muscular, in contrast to the elastic internal lamina 
of the internal thoracic artery (ITA), which makes the RA more prone to spasm and 
atherosclerosis, as well as more sensitive to competitive flow.  
 
Despite encouraging results, use of the RA has been limited worldwide. This may reflect a 
resistance to change from the widely accepted gold standard of CABG with LITA-LAD and 
therefore, a single arterial graft, which presents a short and familiar learning curve, and is 
easily reproducible by the vast majority of surgeons.  Furthermore, current reluctance about 
use of the RA may also relate to the necessity for advanced planning (and patient 
consenting) to its harvest; the need to adapt the arterial line placement and the patient’s 
positioning; perceived concerns about upper extremity arterial insufficiency and 
neurological complications (which fortunately are very rare) (7); and to the requirement for 
additional surgical assistant skills.  
 
Finally, until recently, there has been a lack of compelling evidence supporting a change in 
practice towards widespread use of the RA. In this regard, the recent publication of a 
patient-level meta-analysis of randomized trials comparing the RA to the saphenous vein 
(SV), by Gaudino and colleagues, justifies reviewing the current evidence supporting the use 
of the RA for CABG as a superior alternative to SV, its indications and contraindications, as 
well as specific technical aspects that might impact results (8). These considerations, 
therefore, represent the focus of the present article.  
 
1-Current evidence indicating better clinical outcomes with use of the radial 
artery 
Large propensity-matched observational studies have shown that, in patients where the RA 
was used as the second graft, average survival is longer when compared to patients in 
whom the SV was used in the same setting (9,10). However, any observational study is 
inherently fraught with the potential for “confounding by indication” -a form of selection 
bias-, whether the data are pooled, propensity-matched, subjected to multivariable analysis, 
or none of the above (11). Randomized trials, in this context, are therefore indispensable to 
achieve valid conclusions. 
  
It is logical to hypothesize that the enhanced long-term survival associated with the RA 
versus the SV in CABG performed with the LITA-LAD, in observational studies, may be due to 
a higher patency of the RA. However, among the 7 randomized trials comparing RA vs SV, 
only 3 directly compared the patency of RA and SV and involved more than 100 grafts 
(2,3,6). Only the two trials that extended follow-up beyond the first postoperative year 
found significantly higher patency for the RA (2,3). In contrast, comparable patency rates 
between the RA and SV were observed in the Veterans Administration, although the follow 
up was only 1 year (6)  
Importantly, none of these RCT was powered to show a difference in clinical outcomes. A 
2014 study-level meta-analysis of randomized trials found a significantly lower rate of 
repeat revascularization but no reduced incidence of cardiac death and myocardial 
infarction in the RA group (12). Based on those observational outcome and RCT patency 
data, the ESC-EACTS 2014 MR Guidelines (Class I, LOE B) stated that the use of the RA at 
CABG is recommended over the SV, for target vessels with a high degree of stenosis (13). 
Similarly, the STS Arterial Revascularization Guidelines gave a class IIa (Level of Evidence: B) 
recommendation to the use of the RA (14). 
 
To overcome the sample size limitations of individual trials in detecting differences in 
clinical outcomes, as well as some of the bias inherent to study-level meta-analyses, 
Gaudino et al. recently published a patient-level meta-analysis of randomized trials, where 
RA grafts were compared with SV grafts for CABG (15). The meta-analysis included only 
trials in which mid-term (≥2 years) outcomes were available. The primary endpoint 
consisted of all-cause mortality, myocardial infarction (MI), and repeat revascularization 
(RR) during follow-up. Graft patency represented a secondary endpoint. A total of 6 
randomized trials were selected, with a total of 1305 patients in whom individual data were 
analysed. Because of the design of the trials, the primary endpoint analysis was conducted 
on 5 trials and the secondary endpoint analysis was conducted on 4. After a mean follow-up 
of 60 months, the incidence of adverse cardiac events was significantly lower with the use 
of RA grafts (hazard ratio, 0.67; 95% confidence interval [CI], 0.49 to 0.90; P = 0.01). Use of 
the RA was also associated with a lower incidence of MI (hazard ratio, 0.72; 95% CI, 0.53 to 
0.99; P = 0.04), and a lower incidence of RR (hazard ratio, 0.50; 95% CI, 0.40 to 0.63; 
P<0.001). However, the effect on MI was modest, and could have been the result of 
multiple testing;  overall, the strongest effect was seen for repeat revascularization. 
Notably, there was no significant difference in all-cause mortality (hazard ratio, 0.90, RA 
versus SV, respectively; 95% CI, 0.59 to 1.41; P = 0.68).  
 
The secondary endpoint of the patient-level meta-analysis was graft patency, using the 
Fitzgibbon classification (15). At follow-up angiography (mean follow-up, 50 months) the use 
of RA grafts was associated with a significantly lower risk of occlusion (hazard ratio, 0.44; 
95% CI, 0.28 to 0.70; P<0.001), which provides a plausible explanation for the observed 
differences in clinical outcomes. 
 
Although meta-analysis of individual patient data is the gold-standard for synthesizing 
evidence across clinical studies, limitations also must be acknowledged. Each trial included 
very selected patients, used different inclusion and exclusion criteria, and involved various 
surgical techniques. The total number of patients (n=1036) and the total number of events 
(166 experiencing the primary endpoint; 82 deaths) was low. Repeat revascularization, the 
statistically strongest effect, driving the primary endpoint, may have been inflated as 5 of 
the 6 included trials had primary angiographic endpoints and systematic angiographic 
follow-up. Finally, it is unknown to what extent the patients and care personnel were 
blinded to group assignment.  
 
Taken together, these data reveal that although CABG is the most studied procedure in 
cardiac surgery, we still do not have a robust  answer to whether a second arterial conduit 
(right internal thoracic or radial artery) improves clinical outcomes. Observational data 
universally point in the direction of better outcomes with the use of more than one arterial 
conduit, including the RA. However, this can be due to unmeasured and unmatchable 
confounders, leading to selection and treatment allocation biases even in propensity-
matched series (17). Furthermore, demonstrating that better patency from a second arterial 
graft translates into improved survival is difficult to achieve, as survival after CABG is in large 
part determined by the status of the LAD, while grafts to non-LAD vessels may be more 
likely to affect other cardiac endpoints. The ART trial, which compared revascularisation 
using two internal thoracic arteries vs LITA-LAD plus vein grafts in 1554 patients, did not 
show a mortality benefit with the multiple arterial revascularization strategy, even though 
methodological issues, such as a high treatment crossover rate, might limit the 
generalizability of these findings (18). As such, another trial, appropriately powered for 
clinical endpoints, inclusive of the RA as an important -and potentially preferred- second 
arterial conduit, and with particular attention to surgical expertise and the curtailing of 
crossovers, is warranted. The latter considerations form the basis of the internationally-
funded and currently ongoing ROMA study (19).  
 
2-Indications and -Contra-indications 
 
The Achilles’ heel of the RA as a conduit for CABG is competitive flow through a moderately 
stenotic native target vessel, resulting in diminished RA flow and leading to a diffusely 
narrowed RA (20). When it occurs, this entity can be observed on coronary angiography and 
has been called the RA “string sign” (21). Not surprisingly, this condition has negative 
impacts on graft durability and clinical outcomes. Based on this physiologic concern, current 
guidelines advise that RA grafts be placed on target vessels with a high- grade upstream 
stenosis. In planning the appropriate deployment of RA grafts, it is worth remembering that 
although RA graft patency may decline with decreasing levels of proximal target vessel 
stenosis, it appears at least comparable to SV for the same level of target vessel stenosis 
(20).  An alternate strategy to guide the use of the RA may be to consider the RA’s cross-
sectional area compared to the minimal cross-sectional area at the maximal target vessel 
stenosis (22), although external clinical validation remains pending.   
 
Contraindications for use of the RA are poor collateral ulnar flow jeopardizing hand 
perfusion, diminutive size, and excessive atherosclerosis or calcification. Depending on the 
method used to assess the collateral circulation and on the cutoff used, 5-15% of RAs are 
deemed not to be usable for CABG. Diffuse calcification of the RA is not rare in patients with 
end-stage renal dysfunction or peripheral vascular disease, and is a contra-indication for RA 
use. Patients with vasospastic disorders or those requiring vascular access for dialysis also 
should not have their RA utilized at CABG. Finally, in patients who have undergone trans 
radial catheterization (TRC), use of the instrumented RA is discouraged. Reports have shown 
that TRC results in endothelial injury and vasomotor dysfunction, which may take months to 
recover and may result in premature graft failure (23).  
 
What are then the modern indications for RA use at CABG, and what does the recent 
patient-level meta-analysis add to our knowledge? We believe that the use of the RA should 
de facto be considered during the planning of every CABG operation, given its easy 
harvesting, versatility in reaching all and any target vessels, its peri-operative safety 
comparable to traditional single arterial techniques, and its now clearly demonstrated 
superior late graft patency compared with the traditionally harvested SV (24). Of note, a no-
touch technique for SV harvesting was shown to provide a significantly higher late graft 
patency compared with a traditional SV harvesting method (25); however, randomized 
comparisons of using no-touch SV versus the RA at CABG are lacking.  
 
Compared to the right ITA, the RA is now associated with stronger evidence of a clinical 
benefit and allows greater flexibility in terms of grafting strategy. Furthermore, its use does 
not increase the risk of sternal wound complications. Use of the RA is therefore particularly 
recommended in patients who have good life expectancy, who are at higher risk of sternal 
wound infection, such as obese patients, patients with diabetes or COPD (26), and for whom 
a complex grafting strategy (sequentials, baby Y-, and Y-grafts) is entertained. The RA is also 
easier to handle and often longer than the right ITA, has a more favorable volume/outcome 
relationship (24), and its use is probably more technically reproducible at the beginning of 
the learning curve in multi-arterial grafting.  
 
Overall, the choice of conduits and grafting strategy for CABG, as many of our surgical 
decisions, is based in part on evidence, and in part on opinion, skills, and experience. To 
optimize outcomes in cardiac surgical practice, “the devil is in the details” wit how to choose 
the right procedure for the right patient and how to execute it perfectly. It is presumed, as is 
the case with data derived from surgical RCTs, that those same patient selection and 
“details” were mastered by the experts who have performed the studies included in 
Gaudino et al.’s patient-level meta-analysis, and that the external generalizability of these 
findings may be centre- and surgeon-specific. 
 
 
3-Technical aspects 
 
Evaluation of the collateral circulation of the hand 
To date, no large-scale study has compared the different methods used to assess the 
adequacy of the ulnar collateral circulation to the hand and, as such, no consensus exists on 
which preoperative exam/evaluation should be performed prior to harvesting the RA for 
CABG (27). Although some groups have reported reliable results by using the clinical, 
modified Allen’s test as a screening tool (and reserving more complex tests only to cases 
with a borderline Allen’s test) (28), many surgeons prefer to have an objective evaluation in 
all patients. Pulse-oximetry-based Allen’s test, Doppler, Echo-Doppler, and plethismography 
have all been used with good results (29). In addition, Echo-Doppler offers the advantage of 
evaluating the RA’s diameter, the presence of atherosclerotic plaques, and can identify 
anatomical variations (high origin, high termination, or agenesia)  
 
Harvesting 
One of the purported reasons for the poor patency reported in the first RA series from the 
1970’s may have been the high degree of trauma from harvesting. Although several possible 
technical variations exist for RA harvesting, the integrity of the conduit (and in particular of 
the endothelial layer) is of paramount importance and must be a priority for the surgeon. 
The thick muscular component of the RA makes the conduit prone to spasm, and a well-
preserved and functional endothelial layer is key to modulating the vascular reactivity of the 
artery (30). 
Traditionally, the RA has been harvested by using an open method, but minimally invasive 
and endoscopic harvesting are now employed by many. Several comparative studies and 
meta-analyses have reported no difference between the different techniques, in terms of 
early and long-term clinical results (31); however, these studies were underpowered to 
detect differences in clinical outcomes. RA harvesting is associated with a low incidence of 
transient forearm dysesthesia and paresthesia and their incidence was similar between the 
open and endoscopic methods (32). Not surprisingly, endoscopic techniques provide better 
cosmetic results. 
Although in most of the published series the RA has been harvested as a pedicle, 
skeletonization has been proposed by some groups (29). There is very limited evidence on 
the comparison of the two techniques in terms of patency rate. However, due to the 
aforementioned concerns about possible endothelial damage during harvesting and the lack 
of data suggesting a clinical advantage (as opposed to the case of the RITA), skeletonization 
is currently not recommended or viewed as a likely beneficial approach for the RA. Use of 
the harmonic scalpel facilitates both open and endoscopic harvesting, and may be a useful 
tool to reduce operative time. 
A key part of the use of the RA is the preparation of the conduit. The RA fascia must be 
meticulously opened to assure full dilatation of the artery. Intraluminal injection of 
vasodilators (usually papaverine or milrinone) may increase the size of the conduit and 
prevent postoperative spasm. There is no agreement on the optimal composition  of the 
intraoperative RA bathing solution, which aims both to minimize endothelial injury and 
optimally vasodilate the RA graft.  It is important to note that the RA has a very thick 
muscular media, so it is unlikely that intraluminal administration of anti-spasmodic agents 
alone is enough to reach all vascular wall layers. For this reason, some authors have 
recommended to supplement intraluminal vasodilatation with sub-adventitial injection of 
vasorelaxing agents (33). 
 
Grafting strategy 
The RA has an almost ideal length and diameter to be used as a simple, or sequential Y- or T-
graft. Compared to the RITA, use of the RA greatly reduces the technical complexity of the 
operation and reduces the risk of sternal wound complications. However, composite grafts 
are more sensitive to competitive flow than aortic-based grafts and this is particularly 
relevant for a graft with high spastic potential like the RA. 
 
Secondary prevention 
The majority of the groups prescribe calcium channel blockers or nitrate for 3-6 months 
after the operation in patients with RA grafts, although the evidence supporting their use is 
weak. In general, the use of a dihydropyridine agent for at least 3 months after surgery is 
recommended, although some groups do not use any long term anti-spasmodics. 
 
 
4-In Summary 
Although the impact of RA on mortality is still unproved, the  Radial Artery Database 
International Alliance patient-level meta-analysis has brought additional support for the use 
of the RA in coronary surgery providing solid evidence of a better patency of the RA 
compared with the SV and suggesting the possibility of better outcomes associate with its 
use. Much has been learned in the past 50 years of CABG practice about the use and 
behavior of arterial and venous grafts, but we are still learning and further research is 
needed. Unfortunately, we do not have a strong evidence basis for selecting bypass grafts 
beyond great confidence in the left ITA to the LAD and superior arterial conduit patency. A 
large confirmatory trial on the use of multiple versus single arterial grafts for coronary 
bypass is currently under way (Randomized comparison of the clinical Outcome of single 
versus Multiple Arterial grafts: the ROMA Trial (34). Until the results of ROMA will be 
available, selection of the second (and third) coronary graft will be guided by patient 
characteristics, coronary disease patterns, and centre/operator experience.  
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